# Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis

> **NCT02965599** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 3 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** GSK3117391
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02965599
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-27
- **Primary completion:** 2017-11-14
- **Final completion:** 2017-11-14
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** The study was terminated following an internal review of the company's current research and development portfolio.
- **Last updated:** 2020-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02965599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02965599, "Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02965599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*